Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
暂无分享,去创建一个
Steven J. M. Jones | Richard A. Moore | E. Pleasance | M. Marra | A. Mungall | K. Mungall | E. Zhao | S. Yip | G. Taylor | Yussanne Ma | Martin R. Jones | J. Grewal | J. Laskin | Yaoqing Shen | D. Renouf | T. Ng | E. Chapman | H. Lim | R. Moore | M. Bonakdar | M. Chahal | Steven J. M. Jones
[1] E. Pleasance,et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Iwama,et al. Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies , 2017, The Journal of experimental medicine.
[3] P. Jänne,et al. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models , 2017, Clinical Cancer Research.
[4] M. Ahn,et al. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01) , 2017, Cancer.
[5] C. Moskaluk,et al. A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma , 2017, Clinical Cancer Research.
[6] E. Lenkiewicz,et al. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma , 2017, Oncotarget.
[7] M. Berger,et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform , 2017, JAMA oncology.
[8] C. Antonescu,et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] I. Ellis,et al. Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer , 2016, Modern Pathology.
[10] M. Hyrcza,et al. Gene of the month: BAP1 , 2016, Journal of Clinical Pathology.
[11] R. Weber,et al. In‐depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type , 2016, Cancer.
[12] R. Ferrarotto,et al. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma , 2016, Current opinion in oncology.
[13] L. Wood,et al. Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma , 2016, Cancer Prevention Research.
[14] T. Gonda,et al. Adenoid Cystic Carcinoma Can Be Driven by MYB or MYBL1 Rearrangements: New Insights into MYB and Tumor Biology. , 2016, Cancer discovery.
[15] D. Hayes,et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Huining Kang,et al. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. , 2016, Cancer discovery.
[17] P. A. Futreal,et al. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations , 2015, Clinical Cancer Research.
[18] M. Stratton,et al. Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.
[19] Steven J. M. Jones,et al. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers , 2015, Cold Spring Harbor molecular case studies.
[20] O. Mariani,et al. Genomic landscape of adenoid cystic carcinoma of the breast , 2015, The Journal of pathology.
[21] B. Carneiro,et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling , 2015, Oncotarget.
[22] P. Bradley,et al. Adenoid cystic carcinoma of the head and neck--An update. , 2015, Oral oncology.
[23] Diane D. Liu,et al. Phase II study of gefitinib in patients with advanced salivary gland cancers , 2015, Head & neck.
[24] J. Xie,et al. NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma , 2014, Oncotarget.
[25] Steven J. M. Jones,et al. JAGuaR: Junction Alignments to Genome for RNA-Seq Reads , 2014, PloS one.
[26] P. Stephens,et al. Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies , 2014, The American journal of surgical pathology.
[27] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[28] M. Stratton,et al. Whole exome sequencing of adenoid cystic carcinoma. , 2013, The Journal of clinical investigation.
[29] C. Moskaluk,et al. Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming. , 2013, The Journal of clinical investigation.
[30] Benjamin J. Raphael,et al. The Mutational Landscape of Adenoid Cystic Carcinoma , 2013, Nature Genetics.
[31] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[32] Thomas Krausz,et al. BAP1 and cancer , 2013, Nature Reviews Cancer.
[33] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[34] R. Ferris,et al. Molecular biology of adenoid cystic carcinoma , 2012, Head & neck.
[35] L. Siu,et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[37] J. Reis-Filho,et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers , 2012, The Journal of pathology.
[38] P. A. Futreal,et al. Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome , 2011, Clinical Cancer Research.
[39] A. Argiris,et al. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck , 2011, Cancer.
[40] R. Chole,et al. Adenoid cystic carcinoma: a rare clinical entity and literature review. , 2011, Oral oncology.
[41] Steven J. M. Jones,et al. De novo assembly and analysis of RNA-seq data , 2010, Nature Methods.
[42] R. Weber,et al. Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance , 2010, Clinical Cancer Research.
[43] J. Reis-Filho,et al. Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas) , 2010, Journal of Clinical Pathology.
[44] H. Horlings,et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.
[45] Inanç Birol,et al. De novo transcriptome assembly with ABySS , 2009, Bioinform..
[46] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[47] L. Mariani,et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. , 2009, Oral oncology.
[48] Steven J. M. Jones,et al. Abyss: a Parallel Assembler for Short Read Sequence Data Material Supplemental Open Access , 2022 .
[49] A. Chase,et al. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.
[50] D. Hayes,et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Y. Anavi,et al. Adenoid Cystic Carcinoma of the Salivary Glands: A 20-year Review with Long-Term Follow-Up , 2005, Ear, nose, & throat journal.
[52] E. Lamont,et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J. Roh,et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. , 2003, Archives of otolaryngology--head & neck surgery.
[54] T. Saku,et al. Basement membranes in adenoid cystic carcinoma an immunohistochemical study , 1992, Cancer.
[55] M. Hallett,et al. Absolute assignment of breast cancer intrinsic molecular subtype. , 2015, Journal of the National Cancer Institute.